A critical role for the NFkB pathway in multiple myeloma. - Wikidata - thesis-toulmin - TriplyDB

A critical role for the NFkB pathway in multiple myeloma.

A critical role for the NFkB pathway in multiple myeloma.

http://www.wikidata.org/entity/Q34165181

about

P62: An emerging oncotarget for osteolytic metastasis The cnidarian origin of the proto-oncogenes NF-κB/STAT and WNT-like oncogenic pathway drives the ctenophores (Review)Emerging roles of PDGF-D in EMT progression during tumorigenesis Aberrant nuclear factor-kappa B activity in acute myeloid leukemia: from molecular pathogenesis to therapeutic target Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms.Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.Recent advances in antimultiple myeloma drug development.Aberrant regulation of FBW7 in cancer.NCTD promotes Birinapant-mediated anticancer activity in breast cancer cells by downregulation of c-FLIP.The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma Nucleo-cytoplasmic transport as a therapeutic target of cancer Novel tumor suppressor function of glucocorticoid-induced TNF receptor GITR in multiple myeloma.LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.NF-κB and cancer: a paradigm of Yin-Yang.Molecular damage in cancer: an argument for mTOR-driven aging Recent progress in targeting cancer.Interleukin-6 counteracts therapy-induced cellular oxidative stress in multiple myeloma by up-regulating manganese superoxide dismutase Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits.Genetics of primary intraocular tumors Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB.Saikosaponin A inhibits influenza A virus replication and lung immunopathology.DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma.Relationship between circulating BAFF serum levels with proliferating markers in patients with multiple myeloma An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signalling pathway.URI regulates tumorigenicity and chemotherapeutic resistance of multiple myeloma by modulating IL-6 transcription.Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model Emerging pathways as individualized therapeutic target of multiple myeloma.Novel NF-κB inhibitors: a patent review (2011 - 2014).B-cell activating factor in the pathophysiology of multiple myeloma: a target for therapy?RNA interference for multiple myeloma therapy: targeting signal transduction pathways.Tuning the proteasome to brighten the end of the journey.Microvesicles derived from normal and multiple myeloma bone marrow mesenchymal stem cells differentially modulate myeloma cells' phenotype and translation initiation.Autocrine and Paracrine Interactions between Multiple Myeloma Cells and Bone Marrow Stromal Cells by Growth Arrest-specific Gene 6 Cross-talk with Interleukin-6.TRAF6 is required for BLyS-mediated NF-κB signaling in multiple myeloma cells.Systemic modeling myeloma-osteoclast interactions under normoxic/hypoxic condition using a novel computational approach Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2--implications for a combinatorial treatment.Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study.The BCR-ABL/NF-κB signal transduction network: a long lasting relationship in Philadelphia positive Leukemias RelA and RelB cross-talk and function in Epstein-Barr virus transformed B cells.Linear polyubiquitin chains: a new modifier involved in NFκB activation and chronic inflammation, including dermatitis.

P2860

Q26753091-E057CA88-57A9-4693-B2D9-CF74E657983C Q26799398-9C159502-8B3F-4F34-A70C-8397F7FF5570 Q26859634-C9452989-D6EB-4F61-91E7-E4E914CD49BC Q26995561-1C6B3827-79B0-48AA-9CF7-8A6E9D0F24EF Q27692033-11C4E9AA-154C-439D-A088-150E564BC23C Q30424831-51C4B463-FA75-40CE-9D63-23C5889E2E72 Q33416297-CC1CABF3-6F7D-41B2-BA65-C7D2A7E90004 Q33688508-7DF471A0-BCD1-4D4C-AA9F-55FD8DB47BF6 Q33688860-FBC8A7FA-47F1-467A-8E1C-7735F5E30949 Q33709470-F732492B-1547-44CF-ACCD-E533519E9A6D Q34452108-12EC3EA3-8A9A-4380-8388-A8721D0D354A Q34778972-02BDCA8D-2CC6-4E20-8F51-EFC891E63C5A Q35149611-DD0CD8D0-066A-461D-A79C-2CDC64CBF684 Q35232248-6E178574-50CE-48C6-B1FB-70DC1F74C117 Q35740772-BC14218C-DAFD-4A95-B573-54817B2DB28C Q35740782-C0004687-9156-4EBB-AE78-2D4A1F088B96 Q36002035-86C36791-8FFB-458B-9A62-8C9337B9629D Q36150369-F947A002-B410-4042-9FD2-242CC5B57CBE Q36216850-71B6E6FB-8B98-4354-B900-7540146394E9 Q36392184-7E3FCC87-7618-4BC2-B06D-4E6D2C6EE9FF Q36618923-A501B14E-11B7-469B-BEF3-D991FD173370 Q37031293-A53F9FAF-96E4-4F8E-A88A-EDAB220DB565 Q37054982-9A3617A0-2F12-4CAE-AB59-D86C70F08589 Q37459662-AC505356-925A-459D-BA96-48B0F752CAD0 Q37680154-90E549C6-7CB1-432B-BFA3-F86764EE7EF1 Q37718435-CA6F3DE5-66D6-40BA-9B79-7E68EF26D5CD Q38112176-96CD7C0A-56BF-4707-9C42-8CB96E70CABB Q38305549-41754E31-36BA-4CC7-B8D7-FB4DAA205909 Q38365867-2FDFE257-E231-47D8-82AD-C3C9E8A99D49 Q38550480-1CD30086-FBFA-4B40-AE07-95CA34960D1C Q38559265-2C316E6C-E181-4847-9CCE-355413C559DF Q38609866-2EDA6EBF-F8C3-4A51-A146-5D15E3E1E4B4 Q38718211-62CB9C58-ABC3-469B-BD80-E122FE663988 Q38838441-23886771-07E3-4BD0-B82F-E82B44D6C9F0 Q38843122-98C87C01-D6CA-453A-A616-2E0A4DB50069 Q38868257-DA280324-3655-40C9-8F21-D094B53D4F61 Q38882194-096A19ED-77A6-4546-B634-CD7E1CF530FA Q38937733-E2FCC77D-8FF5-49A9-AB18-F845C10A457D Q39093157-4B2B3722-CD49-42C0-9376-E9622D418EDE Q39177871-26314D8C-4245-4D00-8BAC-7E165429ED62

P2860

A critical role for the NFkB pathway in multiple myeloma.

http://www.wikidata.org/entity/Q34165181

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

A critical role for the NFkB pathway in multiple myeloma.

@ast

A critical role for the NFkB pathway in multiple myeloma.

@en

A critical role for the NFkB pathway in multiple myeloma.

@nl

type

label

A critical role for the NFkB pathway in multiple myeloma.

@ast

A critical role for the NFkB pathway in multiple myeloma.

@en

A critical role for the NFkB pathway in multiple myeloma.

@nl

prefLabel

A critical role for the NFkB pathway in multiple myeloma.

@ast

A critical role for the NFkB pathway in multiple myeloma.

@en

A critical role for the NFkB pathway in multiple myeloma.

@nl

P1433

Q34165181-9FA40E37-C776-43EF-92AC-BCA0894DF8EC

P1476

Q34165181-ACC40AC7-6246-49C7-8E9D-98D1648FCC6D

P2093

Q34165181-5C2688E8-DD0D-476B-AAAB-D430ECE4581C

Q34165181-79A510FA-7A5D-43BD-8622-7C595B6B3473

P2860

Q34165181-0C62524A-994A-42BE-B1CC-01FC3955C0C6

Q34165181-0C657649-2437-4039-AC9D-0C4E4D7710E3

Q34165181-107023E7-53C0-4910-8A21-9D9FA9CDF6E0

Q34165181-134564F4-88AC-4EF6-9042-34158C9FE179

Q34165181-1C05AAAC-6555-4099-A4CC-BF66C9F2D609

Q34165181-1C81FF38-D6D5-4DBD-B5C3-12D52196F9F7

Q34165181-2E76C783-74E1-4044-B398-35EDB97302BE

Q34165181-301B6793-113D-4B14-9C7B-D42F1233375B

Q34165181-30AE2770-8B1A-4993-A74C-F3ADA874FD8B

Q34165181-322156C2-A1DE-420F-B784-C950B7BD1074

P304

Q34165181-FC9D2F14-1A2A-4AE3-BC89-DFD25D525A0B

P31

Q34165181-B55FD08A-16A3-4338-AA46-0B924A2D6413

P356

Q34165181-F3A9D23F-A194-47CE-A444-F0E0D6EE964D

P407

Q34165181-C22BFDB6-BA9C-4648-806F-CA22DE5C294D

P433

Q34165181-1C14B5E4-3AF9-494F-B66B-382CF56705B1

P478

Q34165181-033D1082-EDE3-4BC7-ACA3-7CE19033BD5D

P577

Q34165181-7E5D9FC7-BF0F-4E82-9649-616AECA2A303

P5875

Q34165181-F739E9B3-AA6F-47FC-9F21-91671F278E28

P698

Q34165181-73B45C71-ED81-4899-8D6D-CB28FBCA27D9

P932

Q34165181-31B1719A-CA25-49A4-A84D-AC86DF84FC29

P356

P1433

P1476

A critical role for the NFkB pathway in multiple myeloma.

@en

P2093

W Michael Kuehl

http://www.w3.org/2001/XMLSchema#string

Yulia N Demchenko

http://www.w3.org/2001/XMLSchema#string

P2860

TNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activation

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20

The TRAF6 ubiquitin ligase and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in T lymphocytes

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation

Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

Aberrant rel/nfkb genes and activity in human cancer

Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway

P304

59-68

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.109

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47300909

http://www.w3.org/2001/XMLSchema#string

P698

20890394

http://www.w3.org/2001/XMLSchema#string

P932

2947827

http://www.w3.org/2001/XMLSchema#string